메뉴 보기
link 세부 정보
정보 바로가기 : Amgen's Blincyto OKed for consolidation therapy in ALL, shifting treatmen...
Amgen's Blincyto OKed for consolidation therapy in ALL, shifting treatmen...[카테고리 설정이 아직되어 있지 않습니다.]
Additionally, the three-year relapse-free survival (RFS) rate was 80 percent in the Blincyto group versus 64 percent in the chemotherapy-only group. "These findings suggest that Blincyto not only...
